Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Inclusion Criteria: * Written informed consent * Stable chronic renal disease patients receiving peritoneal dialysis for at least 16 weeks prior to the screening * intact parathyroid hormone value ≥ 240 pg/mL at the screening * Corrected serum calcium ≥ 8.4 mg/dL at the screening Exclusion Criteria: * Patients with primary hyperparathyroidism * Patients who received cinacalcet within 2 weeks prior to the screening * Patients who began to take or changed the dose/dosing regimen of active vitamin D/its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening * Patients who underwent parathyroidectomy and/or parathyroid intervention * Patients with uncontrolled hypertension and/or diabetes * Patients with severe heart disorder * Patients with severe hepatic disease * Patients who take investigational drug in another clinical trial within 12 weeks prior to the screening * Patients who have been judged ineligible to participate in the study by the investigator